HRP20231691T1 - Pripravak za upotrebu u liječenju promjena u crijevima - Google Patents
Pripravak za upotrebu u liječenju promjena u crijevima Download PDFInfo
- Publication number
- HRP20231691T1 HRP20231691T1 HRP20231691TT HRP20231691T HRP20231691T1 HR P20231691 T1 HRP20231691 T1 HR P20231691T1 HR P20231691T T HRP20231691T T HR P20231691TT HR P20231691 T HRP20231691 T HR P20231691T HR P20231691 T1 HRP20231691 T1 HR P20231691T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- core
- extract
- outside
- preparation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 8
- 230000004075 alteration Effects 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- 239000012055 enteric layer Substances 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 8
- 239000001069 triethyl citrate Substances 0.000 claims 6
- 235000013769 triethyl citrate Nutrition 0.000 claims 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 4
- 239000004401 Anionic methacrylate copolymer Substances 0.000 claims 4
- 239000001856 Ethyl cellulose Substances 0.000 claims 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 4
- 239000005642 Oleic acid Substances 0.000 claims 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 4
- 235000019458 anionic methacrylate copolymer Nutrition 0.000 claims 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims 4
- 229920001249 ethyl cellulose Polymers 0.000 claims 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 4
- 229940057917 medium chain triglycerides Drugs 0.000 claims 4
- 239000000661 sodium alginate Substances 0.000 claims 4
- 235000010413 sodium alginate Nutrition 0.000 claims 4
- 229940005550 sodium alginate Drugs 0.000 claims 4
- 206010013554 Diverticulum Diseases 0.000 claims 3
- 229920002770 condensed tannin Polymers 0.000 claims 3
- 239000010410 layer Substances 0.000 claims 3
- 210000002784 stomach Anatomy 0.000 claims 3
- 239000000454 talc Substances 0.000 claims 3
- 235000012222 talc Nutrition 0.000 claims 3
- 229910052623 talc Inorganic materials 0.000 claims 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 3
- 208000012258 Diverticular disease Diseases 0.000 claims 2
- 241000196324 Embryophyta Species 0.000 claims 2
- 235000021355 Stearic acid Nutrition 0.000 claims 2
- 235000012511 Vaccinium Nutrition 0.000 claims 2
- 241000736767 Vaccinium Species 0.000 claims 2
- 239000000908 ammonium hydroxide Substances 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000008117 stearic acid Substances 0.000 claims 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- 208000004623 Colonic Diverticulitis Diseases 0.000 claims 1
- 208000006074 Colonic Diverticulosis Diseases 0.000 claims 1
- 206010013530 Diverticula Diseases 0.000 claims 1
- 206010013559 Diverticulum intestinal Diseases 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 235000020237 cranberry extract Nutrition 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (12)
1. Pripravak za oralnu primjenu, na koji se odnosi („CR”), koji sadrži ili se umjesto toga sastoji od:
(i) jezgre koja sadrži ili se umjesto toga sastoji od ekstrakta (a) barem jedne biljke iz roda Vaccinium i barem jednog sastojka (b) prihvatljivog za upotrebu u farmaceutske ili prehrambene svrhe;
(ii) želučanootpornog sloja izvan jezgre (i) koji potpuno oblaže (i) i sadrži barem jedan sastojak (c) prihvatljiv za upotrebu u farmaceutske ili prehrambene svrhe, pri čemu navedeni želučanootporni sloj (ii) može omogućavati oslobađanje ekstrakta (a) u debelom crijevu; pri čemu je navedeni pripravak za upotrebu u prevenciji i/ili liječenju divertikuloze debelog crijeva, patologija ili bolesti povezanih s prisutnošću divertikula, odabranih između divertikularne bolesti, SUDD-a (simptomatska nekomplicirana divertikularna bolest) i divertikulitisa debelog crijeva.
2. Pripravak za upotrebu prema zahtjevu 1, pri čemu je navedeni ekstrakt (a) barem jedne biljke iz roda Vaccinium poželjno suhi ekstrakt prisutan u količini od 150 mg do 600 mg u odnosu na ukupnu masu ekstrakta (a).
3. Pripravak za upotrebu prema zahtjevu 2, pri čemu je navedeni ekstrakt (a) prisutan u količini od 200 mg do 300 mg u odnosu na ukupnu masu ekstrakta (a) i sadrži od 80 % do 99 % proantocijanidina po masi u odnosu na ukupnu masu ekstrakta (a).
4. Pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu je navedeni ekstrakt (a) poželjno suhi ekstrakt brusnice, koji poželjno sadrži PAC-ove (proantocijanidini) u koncentraciji od 5 % do 30 % po masi ili volumenu, na primjer 10 % ili 15 % ili 20 % ili 25 %.
5. Pripravak za upotrebu prema zahtjevu 1, pri čemu navedeni želučanootporni sloj (ii) izvan jezgre (i) ima svojstvo razgradnje i otapanja ovisno o pH vrijednosti i/ili vremenu te se poželjno navedeni sloj (ii) može razgraditi i otopiti pri pH vrijednosti od oko 6,5 do oko 8.
6. Pripravak za upotrebu prema zahtjevu 5, pri čemu se navedeni želučanootporni sloj (ii) izvan jezgre (i) može razgraditi i otopiti pri pH vrijednosti od oko 7 do oko 7,5, poželjno u vremenu od 30 minuta do 120 minuta i još poželjnije od 45 minuta do 90 minuta.
7. Pripravak za upotrebu prema zahtjevu 1 ili 5 ili 6, pri čemu navedeni želučanootporni sloj (ii) izvan jezgre (i) sadrži ili se umjesto toga sastoji od barem jedne tvari odabrane između biotika Eudragard E1207, želučanootpornog polimera, kao što je poli(metil akrilat-ko-metil metakrilat-ko-metakrilna kiselina) 7:3:1, ili drugog anionskog metakrilnog kopolimera, trietil-citrata E1505, talka, etil-celuloze, anionskog metakrilatnog kopolimera i njihovih mješavina, šelaka, natrijeva alginata i njihovih mješavina, škroba i modificiranih škrobova, oleinske kiseline, stearinske kiseline i srednjelančanih triglicerida.
8. Pripravak za upotrebu prema bilo kojem zahtjevu 1 – 7, pri čemu navedeni želučanootporni sloj (ii) izvan jezgre (1) sadrži ili se umjesto toga sastoji od:
– želučanootpornog polimera, kao što je poli(metil akrilat-ko-metil metakrilat-ko-metakrilna kiselina) 7:3:1, ili drugog anionskog metakrilatnog kopolimera: od 5 do 50 mg, od 10 do 35 mg, od 18 do 25 mg;
– trietil-citrata E1505: od 0,1 do 5 mg, od 0,3 do 3 mg, od 0,5 do 2 mg;
– talka: od 1 do 30 mg, od 3 do 20 mg, od 5 do 15 mg.
9. Pripravak za upotrebu prema bilo kojem zahtjevu 1 – 7, pri čemu navedeni želučanootporni sloj (ii) izvan jezgre (i) sadrži ili se umjesto toga sastoji od:
– etil-celuloze: od 5 do 15 mg, od 8 do 12 mg, od 9,97 mg;
– natrijeva alginata: od 5 do 15 mg, od 8 do 12 mg, od 9,30 mg;
– amonijeva hidroksida: od 0,5 do 4 mg, od 1,5 do 3 mg, od 2,34 mg;
– srednjelančanih triglicerida: od 0,5 do 5 mg, od 1,5 do 3 mg, od 2,12 mg;
– oleinske kiseline: od 0,5 do 3 mg, od 1 do 2 mg, od 1,17 mg;
– pročišćene stearinske kiseline: od 0,01 do 0,5 mg, od 0,05 do 0,3 mg, od 0,1 mg.
10. Pripravak za upotrebu prema bilo kojem zahtjevu 1 – 7, pri čemu navedeni želučanootporni sloj (ii) izvan jezgre (i) sadrži ili se umjesto toga sastoji od:
– etil-celuloze: od 5 do 50 mg, od 10 do 30 mg, od 15 do 20 mg;
– titanijeva dioksida: od 0,1 do 15 mg, od 0,5 do 10 mg, od 1 do 5 mg;
– natrijeva alginata: od 0,1 do 5 mg, od 0,3 do 4 mg, od 0,5 do 2 mg;
– oleinske kiseline, stearinske kiseline, srednjelančanih triglicerida: svaki od 0,01 do 3 mg, između 0,05 i 1 mg.
11. Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu navedeni želučanootporni sloj (ii) izvan jezgre (i) sadrži ili se umjesto toga sastoji od:
– biotika Eudragard ® E1207 (Evonik): na primjer, 20,4 mg;
– trietil-citrata E1505: na primjer, 1 mg;
– talka: na primjer, 10,2 mg.
12. Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu navedeni želučanootporni sloj (ii) izvan jezgre (i) sadrži ili se umjesto toga sastoji od:
– etil-celuloze: na primjer, 9,97 mg;
– natrijeva alginata: na primjer, 9,30 mg;
– amonijeva hidroksida: na primjer, 2,34 mg;
– srednjelančanih triglicerida: na primjer, 2,12 mg;
– oleinske kiseline: na primjer, 1,17 mg;
– pročišćene stearinske kiseline: na primjer, 0,1 mg.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102016000122310A IT201600122310A1 (it) | 2016-12-01 | 2016-12-01 | Composizione per uso nella terapia di alterazioni dell'intestino |
| PCT/IB2017/057580 WO2018100551A1 (en) | 2016-12-01 | 2017-12-01 | Composition for use in the treatment of intestinal alterations |
| EP17822783.1A EP3548006B1 (en) | 2016-12-01 | 2017-12-01 | Composition for use in the treatment of intestinal alterations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231691T1 true HRP20231691T1 (hr) | 2024-03-15 |
Family
ID=58455455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231691TT HRP20231691T1 (hr) | 2016-12-01 | 2017-12-01 | Pripravak za upotrebu u liječenju promjena u crijevima |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10881703B2 (hr) |
| EP (1) | EP3548006B1 (hr) |
| JP (1) | JP7321935B2 (hr) |
| KR (1) | KR102508323B1 (hr) |
| CN (1) | CN110430870B (hr) |
| AU (1) | AU2017368931B2 (hr) |
| BR (1) | BR112019011007A2 (hr) |
| CA (1) | CA3045267A1 (hr) |
| DK (1) | DK3548006T3 (hr) |
| ES (1) | ES2968428T3 (hr) |
| FI (1) | FI3548006T3 (hr) |
| HR (1) | HRP20231691T1 (hr) |
| HU (1) | HUE065202T2 (hr) |
| IT (1) | IT201600122310A1 (hr) |
| LT (1) | LT3548006T (hr) |
| PL (1) | PL3548006T3 (hr) |
| PT (1) | PT3548006T (hr) |
| RS (1) | RS65009B1 (hr) |
| SI (1) | SI3548006T1 (hr) |
| WO (1) | WO2018100551A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201900008394A1 (it) * | 2019-06-07 | 2020-12-07 | Sofar Spa | Composizione per uso nel trattamento delle malattie infiammatorie croniche intestinali |
| JP2021045103A (ja) * | 2019-09-20 | 2021-03-25 | 国立大学法人秋田大学 | 貪食能測定方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0935417T3 (da) * | 1996-10-16 | 2009-08-10 | Napo Pharmaceuticals Inc | Enteroformuleringer af proanthocyanidin-polymer-sammensætninger mod diarré |
| US20020054924A1 (en) * | 2000-04-13 | 2002-05-09 | Leahy Margaret M. | Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor |
| US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| US20070243268A1 (en) * | 2005-11-07 | 2007-10-18 | Jaffe Russell M | Compositions for regulating intestinal disorders and methods of use thereof |
| US20070254050A1 (en) * | 2006-05-01 | 2007-11-01 | Quart Barry D | Method for treatment of diarrhea-predominant irritable bowel syndrome |
| DE202010008308U1 (de) * | 2010-08-18 | 2010-10-21 | Rittinghausen, Reiner, Dr. | Zusammensetzung zur nutritiven Ergänzung oder Behandlung bei Harnwegsinfekten und/oder bakteriellen Entzündungen der Schleimhäute |
| ITMI20110409A1 (it) * | 2011-03-15 | 2012-09-16 | Velleja Res Srl | Impiego delle proantocianidine di tipo a2 in forma gastroprotetta per il trattamento della cistiti in fase acuta sostenute da forme batteriche fimbriate |
| WO2014032108A1 (en) * | 2012-08-29 | 2014-03-06 | Borody Thomas J | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions |
| CN102823875A (zh) * | 2012-09-10 | 2012-12-19 | 湖北强森魔芋科技有限公司 | 一种高膳食纤维代餐粉及其制备方法 |
| CA2896795A1 (en) * | 2012-11-26 | 2014-05-30 | Thomas Julius Borody | Compositions for the restoration of a fecal microbiota and methods for making and using them |
| ITMI20130793A1 (it) * | 2013-05-14 | 2014-11-15 | Probiotical Spa | Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti. |
-
2016
- 2016-12-01 IT IT102016000122310A patent/IT201600122310A1/it unknown
-
2017
- 2017-12-01 LT LTEPPCT/IB2017/057580T patent/LT3548006T/lt unknown
- 2017-12-01 BR BR112019011007A patent/BR112019011007A2/pt not_active Application Discontinuation
- 2017-12-01 HR HRP20231691TT patent/HRP20231691T1/hr unknown
- 2017-12-01 ES ES17822783T patent/ES2968428T3/es active Active
- 2017-12-01 KR KR1020197018872A patent/KR102508323B1/ko active IP Right Grant
- 2017-12-01 CA CA3045267A patent/CA3045267A1/en active Pending
- 2017-12-01 RS RS20231235A patent/RS65009B1/sr unknown
- 2017-12-01 CN CN201780074055.9A patent/CN110430870B/zh active Active
- 2017-12-01 US US16/465,511 patent/US10881703B2/en active Active
- 2017-12-01 HU HUE17822783A patent/HUE065202T2/hu unknown
- 2017-12-01 PT PT178227831T patent/PT3548006T/pt unknown
- 2017-12-01 PL PL17822783.1T patent/PL3548006T3/pl unknown
- 2017-12-01 JP JP2019549668A patent/JP7321935B2/ja active Active
- 2017-12-01 SI SI201731468T patent/SI3548006T1/sl unknown
- 2017-12-01 FI FIEP17822783.1T patent/FI3548006T3/fi active
- 2017-12-01 EP EP17822783.1A patent/EP3548006B1/en active Active
- 2017-12-01 WO PCT/IB2017/057580 patent/WO2018100551A1/en active Application Filing
- 2017-12-01 DK DK17822783.1T patent/DK3548006T3/da active
- 2017-12-01 AU AU2017368931A patent/AU2017368931B2/en active Active
-
2020
- 2020-11-23 US US17/102,391 patent/US11690889B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019120187A (ru) | 2021-01-11 |
| CN110430870B (zh) | 2023-05-23 |
| AU2017368931A1 (en) | 2019-07-04 |
| HUE065202T2 (hu) | 2024-05-28 |
| BR112019011007A2 (pt) | 2019-10-08 |
| IT201600122310A1 (it) | 2018-06-01 |
| US11690889B2 (en) | 2023-07-04 |
| WO2018100551A1 (en) | 2018-06-07 |
| US20210077558A1 (en) | 2021-03-18 |
| EP3548006A1 (en) | 2019-10-09 |
| JP2020500934A (ja) | 2020-01-16 |
| EP3548006B1 (en) | 2023-11-15 |
| PL3548006T3 (pl) | 2024-04-29 |
| KR20190111913A (ko) | 2019-10-02 |
| SI3548006T1 (sl) | 2024-02-29 |
| AU2017368931B2 (en) | 2022-12-22 |
| ES2968428T3 (es) | 2024-05-09 |
| DK3548006T3 (da) | 2024-01-02 |
| PT3548006T (pt) | 2024-01-16 |
| LT3548006T (lt) | 2024-01-10 |
| KR102508323B1 (ko) | 2023-03-08 |
| CN110430870A (zh) | 2019-11-08 |
| US10881703B2 (en) | 2021-01-05 |
| CA3045267A1 (en) | 2018-06-07 |
| RS65009B1 (sr) | 2024-01-31 |
| RU2019120187A3 (hr) | 2021-02-19 |
| US20200061141A1 (en) | 2020-02-27 |
| FI3548006T3 (fi) | 2023-12-19 |
| JP7321935B2 (ja) | 2023-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791702A1 (ru) | Терапевтические средства на основе гликанов и связанные с ними способы | |
| EP3154523A1 (en) | Formulation for oral administration containing mesalazine | |
| HRP20211862T1 (hr) | Pripravci za i postupci liječenja anemije | |
| HRP20231691T1 (hr) | Pripravak za upotrebu u liječenju promjena u crijevima | |
| FI3347002T3 (fi) | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa | |
| EA200870449A1 (ru) | Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами | |
| HRP20191474T1 (hr) | Formulacija za liječenje ibs | |
| EA201100565A1 (ru) | Композиции и способы лечения заболеваний кишечника с использованием гранулированного мезаламина | |
| HRP20211269T1 (hr) | Kompozicije prolijeka na bazi monometil fumarata | |
| JP2023549177A (ja) | 遅延放出ソフトゲルカプセル | |
| JP2019509345A5 (hr) | ||
| PH12016500693A1 (en) | Slow-release solid oral compositions | |
| RU2018137323A (ru) | Пероральные фармацевтические композиции никотинамида | |
| HRP20161796T1 (hr) | Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice | |
| WO2017143172A1 (en) | Time release vitamins and minerals in edible oils | |
| RU2016115985A (ru) | Лактоферрин для лечения ibd, вызванного бактериальной инвазией | |
| JP2016535762A5 (hr) | ||
| JP2015120758A5 (hr) | ||
| RU2018100755A (ru) | Комбинированный препарат мозаприда и рабепразола | |
| JP2019513355A5 (hr) | ||
| Khampeng et al. | A novel tablet disintegrant from Ocimum canum seeds | |
| MD3439637T2 (ro) | Procedeu pentru formulări solide de mesalazină | |
| EP2749288A3 (en) | Capsule and composition comprising seed oil | |
| BR112019000282A2 (pt) | forma de dosagem oral contendo um revestimento exterior de liberação rápida | |
| Baek et al. | Effectiveness of Hizikia fusiformis extract on erosive gastritis: a 4-week, randomized, double-blind and placebo-controlled trial |